Given that GLP-1 retains effectiveness in people with type 2 diabetes and its action on insulin secretion is glucose dependent, thus limiting the incidence of hypoglycaemic side-effects, GLP-1 has proved an attractive therapeutic tool, and long-acting GLP-1 analogues have been front-line tools for the treatment of type 2 diabetes for the last decade. Here, INS is linked to type 2 diabetes mellitus.